Newelpharm & Biodeal was established in 2012. Targeting at novel small molecule drug development, Newelpharm & Biodeal has rich experience in pharmaceutical development from pre-IND to NDA. Our top management team is composed of western-trained professionals, and they all have multiple years of working experience in global pharmaceutical and biotech companies. Our business is focused on API production and formulation development. QDB is implemented into our R&D activities, including process design, optimization, scale ups. Our labs are equipped with modern instruments, and operations are guided by internal SOPs.
Newelpharm & Biodeal is located in BioSciKin Park in Xuzhuang, Nanjing. It occupies 10,000 square feet state-of-art laboratories; and employees 40 experienced and talented scientists. Newelpharm & Biodeal believes that R&D is the key for success, and innovation creates value. Biodeal's strategy is to build a pipeline filled with generics and patent drugs for the treatment of cardiovascular, central nerve, inflammatory, antiviral, and cancer. Our business is growing rapidly in both domestic and oversea markets. To further expand our production capacity, Newelpharm & Biodeal is planning to build a cGMP manufacturing facility. Our goal is to make high-quality products accessible to more people and more patients around the world.
In the past few years, Newelpharm & Biodeal has successfully cooperated with some strategic partners in marketing and sales in cancer, cardiovascular, inflammation, infection areas:
Yangtze River Pharmaceutical Group (Top 3 pharmaceutical Group in China)
Jiangsu Wanguard Pharmaceutical (more than 400 M Yuan/year) etc.
The marketing and sales cover more than 5000 hospitals in China. Meantime, Newelpharm & Biodeal also established its own reputation in collaborating with many famous experts in scientific research and pharmaceutical R&D.